UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats.
Sign Up to like & getrecommendations! Published in 2018 at "Bioanalysis"
DOI: 10.4155/bio-2018-0092
Abstract: AIM Mozavaptan is a nonpeptide vasopressin receptor antagonist approved for the treatment of ectopic antidiuretic hormone secretion syndrome. METHODS & RESULTS A simple, rapid and fully validated UPLC/MS-MS method was developed for the quantitation of… read more here.
Keywords: plasma; development estimation; uplc assay; mozavaptan ... See more keywords